Clinical Observation of Lenvatinib,PD-1 Inhibitor Combined with Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
Objective To investigate the clinical efficacy of lenvatinib,programmed death-1(PD-1)inhibitor combined with transcatheter arterial chemoembolization(TACE)in the treatment of unresectable hepatocellular carcinoma(uHCC).Methods A total of 106 patients with uHCC admitted to the People's Hospital of Funan County from July 2020 to July 2023 were selected and divided into the control group(32 cases),the drug group(34 cases)and the combined group(40 cases)based on the different treatment regimens.The patients in the three groups were given TACE,TACE+PD-1 inhibitor,TACE+PD-1 inhibitor+lenvatinib respectively,in which the PD-1 inhibitor was one of Sintilimab Injection,Tislelizumab Injection and Camrelizumab for Injection.All three groups were treated for six weeks.Results The disease control rate(DCR)in the combined group was 90.00%,which was significantly higher than 65.63% in the control group and 70.59% in the drug group(P<0.05).After treatment,the alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBiL),α-fetoprotein(AFP),carcinoembryonic antigen(CEA),α-L-fucosidase(AFU),carbohydrate antigen 199(CA199)levels and Quality of Life Questionnaire-Core 30(QLQ-C30)score in the combined group were significantly lower than those in the control group and drug group(P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion Lenvatinib and PD-1 inhibitor combined with TACE can effectively improve liver function,decrease serum tumor biomarker levels,and improve the quality of life in patients with uHCC.
lenvatinibprogrammed death-1transcatheter arterial chemoembolizationunresectable hepatocellular carcinomaliver functiontumor markerquality of life
国家科技期刊平台
NSTL
万方数据
